药物信息为ERGOTAMINE TARTRATE AND CAFFEINETABLETS, USP1MG/100 MG (West-ward Pharmaceutical Corp.): WARNING
- WARNING
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- CONTRAINDICATIONS
- ADVERSE REACTIONS
- DRUG ABUSE AND DEPENDENCE
- OVERDOSAGE
- HOW SUPPLIED
- Diseases/Conditions Related to ERGOTAMINE TARTRATE AND CAFFEINETABLETS, USP1MG/100 MG (West-ward Pharmaceutical Corp.)
- 外部链接相关的ERGOTAMINE TARTRATE AND CAFFEINETABLETS, USP1MG/100 MG (West-ward Pharmaceutical Corp.)
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of ergotamine tartrate and caffeine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated. (See also CONTRAINDICATIONS and WARNINGS sections)
- Drug Information Provided by National Library of Medicine (NLM).
